AllerGen NCE Inc.

AllerGen - (Allergy, Genes and Environment Network) was launched in 2004 to radically improve the quality of life for allergic/immune disease sufferers. The network is comprised of more than 100 researchers at 20 universities and research facilities plus over 70 Canadian and international partners with three broad programs in immune disease research:

• Program A: Gene environment interactions
• Program B: Diagnostics and therapeutics
• Program C: Public health policy and society

AllerGen encourages investigators to seek patent protection on innovations discovered in their research laboratories. Early-stage break-through technologies that have commercial potential include:
• New diagnostic tests for allergy and asthma (Allergy/asthma gene chips);
• Bio-analytic tests for airborne pollutants and allergens;
• New food products; and
• Clinical trial methodologies that fast-track new allergy and asthma drug candidates.

AllerGen is also promoting the Canadian Healthy Infant Longitudinal Development (CHILD), a Canada-wide multidisciplinary, longitudinal, population-based cohort study in allergy and asthma —the first of its kind in Canada and the world. A pan-Canadian multidisciplinary researcher team hopes to close the knowledge gap relating to the influence of the environment (indoor and outdoor air and exposures) and host genetic factors leading to respiratory disease causing lung impairment—especially in children.

AllerGen NCE Inc.
McMaster University
1200 Main street West, Rm 3120
Michael G. DeGroote Centre
Hamilton On. L3N 3Z5
www.allergen-nce.ca
Tel: 1-905-525-9140 x26092
biolaunch@on.aibn.com